2021
Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic
Yaesoubi R, Havumaki J, Chitwood MH, Menzies NA, Gonsalves G, Salomon JA, Paltiel AD, Cohen T. Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. Medical Decision Making 2021, 41: 386-392. PMID: 33504258, PMCID: PMC8084913, DOI: 10.1177/0272989x21990371.Peer-Reviewed Original ResearchConceptsAdaptive policiesClear decision rulesSocial costsEconomic costsPolicy makersPhysical distancing policiesDecision toolPolicyPhysical distancing interventionsDistancing policiesModel-based experimentsDecision rulesReal-time surveillance dataCostCOVID-19 pandemicMakersShorter overall durationMore complex modelsHealth benefitsComplex modelsPandemicCurrent pandemicCOVID-19BenefitsRules
2020
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi.
Hsieh YL, Jahn A, Menzies NA, Yaesoubi R, Salomon JA, Girma B, Gunde L, Eaton JW, Auld A, Odo M, Kiyiika CN, Kalua T, Chiwandira B, Mpunga JU, Mbendra K, Corbett L, Hosseinipour MC, Cohen T, Kunkel A. Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 643-650. PMID: 33177475, PMCID: PMC8564780, DOI: 10.1097/qai.0000000000002497.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIPT programIPT strategyPreventive therapyContinuous isoniazid preventive therapyMore TB casesHIV-positive adultsCases of tuberculosisAnticipated health effectsComparable health benefitsHIV/AIDSCause deathAntiretroviral therapyTB casesTB controlTB incidenceDrug costsMalawi MinistryMean reductionTuberculosisMycobacterium tuberculosisTherapyAnticipated health impactsHealth effectsHealth benefits
2018
Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model
Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. American Journal Of Epidemiology 2018, 187: 2011-2020. PMID: 29762657, PMCID: PMC6119121, DOI: 10.1093/aje/kwy094.Peer-Reviewed Original ResearchConceptsTB preventionTB eliminationLatent TB infection (LTBI) screeningTB case detectionHigh-risk populationImportant health benefitsTransmission dynamic modelIncident TBActive TBTuberculosis eliminationInfection testingTB controlTB incidenceEpidemiologic evidenceTB transmissionInfection screeningCase detectionTuberculosis trendsUS populationRisk determinantsHealth benefitsTreatment qualityUnited StatesTreatment activitiesTreatment
2016
Identifying cost‐effective dynamic policies to control epidemics
Yaesoubi R, Cohen T. Identifying cost‐effective dynamic policies to control epidemics. Statistics In Medicine 2016, 35: 5189-5209. PMID: 27449759, PMCID: PMC5096998, DOI: 10.1002/sim.7047.Peer-Reviewed Original ResearchConceptsNet health benefitHighest net health benefitHealth benefitsTransmission-reducing interventionsDynamic policiesNovel viral pathogensCurrent interventionsHealth policyMathematical decision modelViral pathogensMonetary outcomesPolicy makersInterventionPolicyDecision modelStatic policyEpidemicEpidemic dataVaccinationVaccinePerformance measures
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility